In Law360, Margaux Hall and Andrew O’Connor Examine 2023 Health Care Policy and False Claims Act Trends
In Law360 articles, health care partner Margaux Hall and litigation & enforcement partner Andrew O’Connor discussed health care policy and False Claims Act 2023 trends to watch.
Margaux explained that the Centers for Medicare and Medicaid will be under inquiry when it selects the inaugural 10 drugs for Medicare’s price negotiations. The 10 drugs will belong to a pool of products with relatively high total costs to Medicare Part D, but the selection process isn't straightforward.
Andrew noted that health care and life sciences companies that contract with or receive grants from the federal government may be subject to scrutiny under the U.S. Department of Justice Civil Cyber-Fraud Initiative. He also said that Medicare Advantage has been on DOJ's short list of False Claims Act priorities.